ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ミコナゾール

Miconazole

HCID 4189
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
22916-47-8
標準SMILES
Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
InChIKey
BYBLEWFAAKGYCD-UHFFFAOYSA-N
分子式
C18H14Cl4N2O
平均分子量
416.1 g/mol
単同位体質量
413.986024

概要

1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole is a member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group. It is a dichlorobenzene, a member of imidazoles and an ether.

名称と識別子

優先名称
Miconazole
IUPAC
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
現地名
ミコナゾール
英語名
Miconazole
分子式
C18H14Cl4N2O
分子量
416.13

名称と別名

miconazole22916-47-8Daktarin IVMiconazolMiconazoloMiconazolum1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazoleDaktarinOravig1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-DTXSID6023319
名称をさらに表示
アムリードDコランゾールミコギンミコフガルダクタリンIVフロリード1-[2,4-ジクロロ-β-(2,4-ジクロロベンジルオキシ)フェネチル]-1H-イミダゾールサラシルトミコナゾールスペクタゾールフロリド-F1-[β-[(2,4-ジクロロベンジル)オキシ]-2,4-ジクロロフェネチル]-1H-イミダゾールミコナゾールゲルフロリード-Fイフェネックエピ-ペバリルギノ-ペバリル1-(2,4-ジクロロフェニル)-1-[(2,4-ジクロロフェニル)メトキシ]-2-(1H-イミダゾール-1-イル)エタンモニスタットIV1-[2-(2,4-ジクロロフェニル)-2-[(2,4-ジクロロフェニル)メトキシ]エチル]-1H-イミダゾールMICONAZOLE BASE1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]- (9CI)r18134mjr1762R 18134MinostateNSC 170986Miconozole
7NNO0D7S5M1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole1H-Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-DTXCID803319Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-NSC170986DermazoleDumicoat

物性

構造計算による物性補完中

XLogP
5.3
極性表面積
27.1 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
6
重原子数
25
形式電荷
0
複雑度
417

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Antibiotics

Pharmaceuticals

PesticidesBiocide
LogP · 2 件

6.1

5.81

Solubility7.63e-04 g/L
Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Antifungal Agents; Dermatologic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Dermatological medicines > Antifungal medicines

Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point159 - 163 °C
Physical DescriptionSolid
Collision Cross Section187.51 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 1% (1 of 104) of reports.

Warning

H302 (98.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 104 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationMiconazole: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - 1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (98.1%)

毒性情報

Exposure RoutesTopical
Toxicity Summary · 1 件

Miconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Miconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.

Signs and Symptoms

化学と産業

薬理情報

ATC Code · 6 件

D01AC02

D - Dermatologicals

S - Sensory organs

G - Genito urinary system and sex hormones

J - Antiinfectives for systemic use

A - Alimentary tract and metabolism

Protein Binding_In vitro_ data suggests that miconazole binds human serum albumin, however, the clinical significance of this observation is unclear.
Pharmacodynamics · 1 件

Miconazole is an azole antifungal that functions primarily through inhibition of a specific demethylase within the CYP450 complex. As miconazole is typically applied topically and is minimally absorbed into the systemic circulation following application, the majority of patient reactions are limited to hypersensitivity and cases of anaphylaxis. Patients using intravaginal miconazole products are advised not to rely on contraceptives to prevent pregnancy and sexually transmitted infections, as well as not to use tampons concurrently.

Mechanism of Action · 1 件

Miconazole is an azole antifungal used to treat a variety of conditions, including those caused by _Candida_ overgrowth. Unique among the azoles, miconazole is thought to act through three main mechanisms. The primary mechanism of action is through inhibition of the CYP450 14α-lanosterol demethylase enzyme, which results in altered ergosterol production and impaired cell membrane composition and permeability, which in turn leads to cation, phosphate, and low molecular weight protein leakage. In addition, miconazole inhibits fungal peroxidase and catalase while not affecting NADH oxidase activity, leading to increased production of reactive oxygen species (ROS). Increased intracellular ROS leads to downstream pleiotropic effects and eventual apoptosis. Lastly, likely as a result of lanosterol demethylation inhibition, miconazole causes a rise in intracellular levels of farnesol. This molecule participates in quorum sensing in _Candida_, preventing the transition from yeast to mycelial forms and thereby the formation of biofilms, which are more resistant to antibiotics. In addition, farnesol is an inhibitor of drug efflux ABC transporters, namely _Candida_ CaCdr1p and CaCdr2p, which may additionally contribute to increased effectiveness of azole drugs.

関連反応

33 件
反応記録を作成
HRID 200761 の反応式
HRID 200761反応物として
HRID 328633 の反応式
HRID 328633反応物として
HRID 328634 の反応式
HRID 328634反応物として
HRID 328635 の反応式
HRID 328635反応物として
HRID 328636 の反応式
HRID 328636反応物として
HRID 328637 の反応式
HRID 328637反応物として
HRID 328638 の反応式
HRID 328638反応物として
HRID 328639 の反応式
HRID 328639反応物として
前へ1 / 5 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
22916-47-8
PubChem CID
4189
DTXSID
DTXSID6023319
ChEMBL
CHEMBL91
ChEBI
CHEBI:82892
UNII
7NNO0D7S5M
EC Number
245-324-5
Nikkaji
J11.471E
融点
159 · 159-163C
沸点
555.1 · 555.1±50.0 °C(Predicted)
比重(密度)
1.5326 · 1.5326 (rough estimate)
屈折率
1.62 · 1.6200 (estimate)
闪点
87 ° · 87°(189°F)
貯蔵温度
Sealed in dry,Room Temperature
溶解性
水に極めて溶けにくく、メタノールに溶けやすく、エタノールに溶けやすい (96%)。
外見
Solid
酸解離定数(Pka)
6.91 · pKa 6.91(H2O,t =25) (Uncertain)
色
ホワイトからオフホワイト
水溶解度
アルコールまたはアセトンに可溶。 DMFまたはクロロホルムにも可溶。水に溶けない
主な用途
医薬品(低分子化合物)
InChI
1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2
InChIKey
BYBLEWFAAKGYCD-UHFFFAOYSA-N
SMILES
Clc1c(ccc(c1)Cl)C(OCc3c(cc(cc3)Cl)Cl)C[n]2cncc2
CAS データベース
22916 · 22916-47-8(CAS DataBase Reference)
NISTの化学物質情報
Miconazole(22916-47-8)
EPAの化学物質情報
1 H-Imidazole, · 1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]- (22916-47-8)

化学的性質

化学的特性White or almost white powder.

Ingestion of the amounts of the components contained in a tube of cream are unlikely to produce overdosage and toxic effects.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

miconazole

DILI Negative

Topical

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation · 2 件

◉ Summary of Use during Lactation

◈ What is miconazole?

Toxicity DataLD50: 3800 mg/kg (Oral, Mouse) (A308) LD50: 3 gm/kg (Oral, Rat) (A308)
EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Miconazole

1.2

4.9

The recommended dosing schedule for miconazole is the application of one 50 mg buccal tablet to the upper gum region (canine fossa) once daily for 14 consecutive days.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 50 mg/day, Lowest Therapeutic Dose (LTD): 0.6 mg/kg-day, and Screening Dose: 0.0002 mg/kg-day.

1-Jan-22

安全データ

wgk
3
ridadr
3249
hs_code
2933290000
risk_code
22
hazard_code
Xn
safety_code
22-36
hazard_class
6.1(b)
packing_group
III
Hazard Classifications
Acute Tox. 4 OralAquatic Chronic 4
ストレージクラス
11 - Combustible Solids
Biological Half-Life
Miconazole has a terminal half-life of 24 hours.
Metabolism/MetabolitesMiconazole is metabolized in the liver and does not give rise to any active metabolites.
FDA Pharmacological Classification · 6 件

7NNO0D7S5M

MICONAZOLE

Established Pharmacologic Class [EPC] - Azole Antifungal

Chemical Structure [CS] - Azoles

Miconazole is an Azole Antifungal.

MICONAZOLE

MeSH Pharmacological Classification · 4 件

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.

Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism.

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2C9.

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A.

Absorption, Distribution and Excretion · 3 件

Miconazole given to healthy volunteers as a single 50 mg oral tablet produced a mean Cmax of 15.1 ± 16.2 mcg/mL, a mean AUC0-24 of 55.2 ± 35.1 mcg\*h/mL, and a median Tmax of 7 hours (range 2.0-24.1). In these patients measurable plasma concentrations ranged from 0.5 to 0.83 mcg/mL. Topical miconazole is absorbed poorly into the systemic circulation. In pediatric patients aged 1-21 months given multiple topical applications of miconazole ointment for seven days, the plasma miconazole concentration was less than 0.5 ng/mL in 88% of the patients, with the remaining patients having a concentration of 0.57 and 0.58 ng/mL, respectively. Similarly, patients. administered with a vaginal 1200 mg ovule had a mean Cmax of 10.71 ng/mL, mean Tmax of 18.4 hours, and mean AUC0-96 of 477.3 ng\*h/mL.

Miconazole is excreted through both urine and feces; less than 1% of unchanged miconazole is recovered in urine.

A 1200 mg miconazole vaginal suppository resulted in a calculated apparent volume of distribution of 95 546 L while a 100 mg vaginal cream yielded an apparent volume of distribution of 10 911L.

Cellular LocationsCytoplasm

用途と製造

Uses · 2 件

Use (kg; approx.) in Germany (2009): >1000

For topical application in the treatment of tinea pedis (athlete&rsquo;s foot), tinea cruris, and tinea corporis caused by <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, and <i>Epidermophyton floccosum</i>, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.

応用分野 · 2 件

用途アゾール系抗真菌薬真菌の細胞膜構造や機能障害を引き起こす

使用Antifungal;Sterol 14-demethylase inhibitor. Miconazole (Monistat-Derm, Micatin, etc.) is a synthetic imidazole antifungal compound that acts by altering cell membrane permeability. It is effective against most dermatophyte species, P. orbiculare, and C. albicans.

上流・下流製品情報

上流原料

4-クロロフェナシルクロリド2,4-ジクロロベンジルクロリド1-(2,4-ジクロロフェニル)-2-(1H-イミダゾール-1-イル)エタノン2-(2,4-ジクロロフェニル)オキシラン1-(2,4-ジクロロフェニル)-2-(1-イミダゾリル)エタノール2,2',4'-トリクロロアセトフェノン

下流製品

スルコナゾール